Industry & Policy News

[AstraZeneca Canada Inc. (News Wire)] Health Canada has granted a Notice of Compliance for IMFINZI^® (durvalumab), as monotherapy, for the treatment of adult patients with LS-SCLC whose disease has not progressed following platinum-based chemoradiation therapy.

[King's College London] Adults could one day grow their own replacement teeth instead of having fillings – as scientists make a key discovery.

[Nature] iPSCs are being tested to treat blindness, paralysis, Parkinson’s disease and more. Approvals might be around the corner.

[Applied StemCell, Inc.] Applied StemCell, Inc. announced that they have submitted a Type II Drug Master File to the US FDA for their ActiCells^™ GMP hiPSC line.

[Cellino (BioSpace)] Cellino announced its expansion into the Asia-Pacific region through a strategic collaboration with Karis Bio, a leading South Korean cell therapy biotech. The partnership aims to industrialize the world’s first clinical-stage autologous iPSC-derived cell therapy for peripheral artery disease and coronary artery disease.

[XellSmart Biomedical (Suzhou) Co., Ltd] The US FDA officially approved the Investigational New Drug application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy for the treatment of Parkinson’s disease.